LianBio is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It offers a pipeline of nine product candidates across five therapeutic areas, namely cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13, LYR-210 and Sisunatovir. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is being studied for the treatment of hypertrophic cardiomyopathy (HCM) and has potential therapeutic applications for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis and meibomian gland disease. NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Buy US stocks in Australia starting with LIAN. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in LIAN
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.